SGMT Stock Analysis: Buy, Sell, or Hold?
SGMT - Sagimet Biosciences Inc. Series A Common Stock
$7.76
0.60 (8.46%)
▲
5d:
+0.85%
30d:
+20.61%
90d:
+43.08%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 12, 2026
27d
Get Alerted When SGMT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SGMT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: SGMT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SGMT is currently trading at $7.75, which is considered extended relative to its 30-day fair value range of $6.56 to $7.54.
Technical Outlook: Technically, SGMT is in a strong uptrend. The price is approaching resistance at $7.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.5% recently.
Market Sentiment: SGMT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $26.20 (+237.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SGMT is in a strong uptrend. The price is approaching resistance at $7.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.5% recently.
Market Sentiment: SGMT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $26.20 (+237.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.56 -
$7.54
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.5%)
- BULLISH: Trading 237.8% below Wall St target ($26.20)
Trading Range Analysis
30-Day Trading Range
$6.56 -
$7.54
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.96
Resistance Level
$7.95
Current Trend
Strong Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.91
Wall Street Target
$26.20
(+237.8%)
Share & Embed Analysis
Last updated: July 14, 2026 9:25 PM ET
Data refreshes hourly during market hours. Next update: 10:25 PM
Data refreshes hourly during market hours. Next update: 10:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SGMT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
David Happel
SELL
12101 shares
2026-02-10
Thierry Chauche
SELL
1312 shares
2026-02-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 58 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 51 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 60 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$20 | 63 BUY |
